We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection

By LabMedica International staff writers
Posted on 05 May 2025

Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. More...

Late-stage diagnoses often limit available treatment options and result in poorer patient outcomes. Efforts to identify biomarkers in a patient's blood have previously struggled due to the blood-brain barrier, which, while protecting the brain from infection, also prevents potential biomarkers from reaching the bloodstream. To address this issue, researchers have developed a new liquid biopsy method that could transform brain cancer detection by identifying DNA fragments from tumors and immune cells circulating in the blood, potentially allowing for earlier diagnosis. A description of the work has been published in Cancer Discovery.

The innovative liquid biopsy technique, developed by researchers at Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA), has already proven effective in detecting lung cancer and is currently used in clinical settings for lung cancer screening. This method utilizes machine learning, a form of artificial intelligence (AI), to detect patterns in circulating DNA fragments linked to brain tumors. Additionally, it identifies recurring patterns in the genome associated with brain cancer. In a study involving 505 patients from the United States and South Korea, this approach successfully detected brain cancer in approximately 75% of cases. The team later confirmed these results in a second group of around 95 patients from Poland. In contrast, previous liquid biopsy methods have detected brain cancer in fewer than 10% of cases.

A key factor contributing to the success of this approach is its ability to detect immune changes related to brain cancer. Patients with brain tumors exhibit immune suppression throughout their body and a distinct immune cell profile in their blood. These immune changes do not need to cross the blood-brain barrier to be identified. Following this, the team conducted a computer simulation to assess the potential of their liquid biopsy technique for screening the estimated 10 million individuals who visit emergency rooms or primary care clinics annually due to headaches. Typically, these patients are only referred for brain imaging if their physician suspects an underlying issue. However, in the simulation, patients whose liquid biopsy results suggested brain cancer were sent for imaging, which led to the detection of nearly 1,700 additional cancer cases compared to the conventional method. The next step for the team is to design a prospective trial to validate these findings in larger populations at higher risk for brain cancer.

“Our next-generation AI liquid biopsy approach combining DNA fragments and repeating genome patterns may accelerate brain cancer diagnosis,” said Victor E. Velculescu, M.D., Ph.D., co-director of cancer genetics and epigenetics at the cancer center. “It may ultimately allow patients to get care earlier, improving their treatment outcomes.”


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.